Larimar CEO Ben-Maimon Buys 18,050 Shares for ~$50K, Fourth Insider Buy This Week
LRMR sits 43% above its 52-week low of $1.915.
Summary
Larimar's CEO bought 18,050 shares for about $50,000 at a weighted-average $2.7675 — the fourth insider open-market purchase reported this week and the largest single one. Dollar-wise the buys are small, but they cluster right after the company completed its rolling BLA for nomlabofusp.
Key Events · Ownership and Investor Activity · LRMR
-
CEO Open-Market Purchase
President and CEO Carole Ben-Maimon acquired 18,050 shares at a weighted-average $2.7675 on 2026-11-11 for $49,953.38, in trades ranging from $2.765 to $2.77.
-
Holdings After Purchase
Direct ownership rose to 386,326 shares; she also holds 155,778 shares indirectly through five family trusts, over which she disclaims beneficial ownership beyond her pecuniary interest.
-
Fourth Insider Buy This Week
Follows purchases by the CDO (5,000 shares, $13,549), CFO (18,460 shares, ~$50,000) and President/COO (17,800 shares, $49,918) plus director Frank Thomas (8,000 shares, $21,800), bringing 90-day open-market insider buying to roughly $135,000 with no sales.
-
Timing After BLA Completion
Comes two days after the 2026-11-09 8-K disclosing completion of the rolling BLA for nomlabofusp and roughly $128.7 million of cash, against a going-concern warning in the Q2 2026 10-Q.
Analysis · LRMR · Life Sciences
Why it matters: the CEO put about $50,000 of her own money into open-market shares at a weighted-average $2.7675, one day after three other insiders bought. That makes four separate officers and directors buying within the same week, with no insider sales in the last 90 days. Against the company's roughly $280 million market value, the purchases are small — a confidence gesture rather than a conviction trade. The clustering is the signal: it comes two days after Larimar disclosed it finished the rolling BLA for nomlabofusp and held about $128.7 million of cash, even as the last 10-Q carried a going-concern warning. Management buying stock right after a regulatory milestone, while the balance sheet is still flagged as a concern, is the read-through here.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LRMR was trading at $2.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $280.5M. The 52-week trading range was $1.92 to $6.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.